TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01621425

Intervention type: OTHER
Intervention: Lean body mass
Description: Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose

Intervention type: OTHER
Intervention: Lean body mass
Description: Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose

Intervention type: OTHER
Intervention: Total body weight
Description: Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose

Intervention type: OTHER
Intervention: Total body weight
Description: Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose

Intervention type: OTHER
Intervention: bloodsampling
Description: Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model

Intervention type: OTHER
Intervention: bloodsampling
Description: Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
Study: NCT01904786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00719784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Response Imaging
Description: Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
Study: NCT01290263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amgen 386
Description: For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amgen 386
Description: For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
Study: NCT03169959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Saxagliptin tablet
Description: A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Saxagliptin tablet
Description: A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Saxagliptin tablet
Description: A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Saxagliptin tablet
Description: A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Saxagliptin tablet
Description: A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
Study: NCT00105001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT04028089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Modification Group
Description: The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular Diet Group
Description: Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study.
Study: NCT03475277

Intervention type: DRUG
Intervention: Ketamine
Description: Acute administration
Study: NCT02610907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buffer
Description: The sleeve contains phosphate buffered saline buffer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own output
Description: The sleeve contains the subject own ileal effluent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulated output
Description: The sleeve contains simulated output
Study: NCT02004470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active lavage and suction
Description: Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
Study: NCT02718430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Oral immunotherapy targeting VEGFR2
Study: NCT00699049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha blocker
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha blocker
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study: NCT01699503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Dementia Care Program
Description: Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
Study: NCT04237168

Intervention type: DIAGNOSTIC_TEST
Intervention: IgNGS from circulating tumor DNA
Description: 3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
Study: NCT00639782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-X Heart valve replacement
Description: On-X Heart valve replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SJM Heart valve replacement
Description: SJM Heart valve replacement
Study: NCT01534689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia FX-405™ Laser
Description: The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
Study: NCT00997893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate (MPA)
Description: medroxyprogesterone acetate (MPA) (10mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy Placebo
Description: oral placebo pill (0mg Soy Phytoestrogen)
Study: NCT02156726

Intervention type: DRUG
Intervention: low-dose FCR
Description: FCR with attenuated dose of fludarabine and cyclophosphamide
Study: NCT03492944

Intervention type: DRUG
Intervention: Ultrasound Microbubble Contrast Agent
Description: Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel

Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
Study: NCT03026192

Intervention type: DEVICE
Intervention: near infrared spectroscopy
Description: Near infrared spectroscopy will be placed on infants both with and without hsPDA

Intervention type: DEVICE
Intervention: near infrared spectroscopy
Description: Near infrared spectroscopy will be placed on infants both with and without hsPDA
Study: NCT04317365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Women receiving extra remembering by healthcare
Description: Women receiving extra remembering by healthcare in covid infection
Study: NCT01389505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal photocoagulation
Description: Three episodes of panretinal photocoagulation with one week of interval

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab
Description: Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
Study: NCT02415517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training on computer. Six sessions with different tasks: Tiere merken \& Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Test of general knowledge
Description: Training of general knowledge on computer. Six sessions with different topics.
Study: NCT03942900

Intervention type: OTHER
Intervention: Additional biological samples
Description: * Biomonitoring blood sample will be collected: 6 EDTA tubes (6 mL) for PBMC (peripheral blood mononucleated cell), 1 EDTA tube (6 mL) for plasma freezing and 2 EDTA tubes (4 mL) for ctDNA:~  * at baseline,~ * at first tumor assessment (phase 2 in OPTIMANAL study),~ * at second tumor assessment (phase 4 in OPTIMANAL study),~ * at end-point visit.~* A tumor biopsy or archived tumor sample will be mandatory at baseline.
Study: NCT04073251

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KalobaTuss children
Description: Syrup, dosage: 5 ml for 4 times a day for 8 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Syrup, dosage: 5 ml for 4 times a day for 8 days.
Study: NCT03020576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo Hand Robot Device
Description: This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
Study: NCT01153321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 100mg Oral dose od

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD2423 Placebo
Description: Oral dose od
Study: NCT03836716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
Study: NCT01994759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticosteroid injection
Description: Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticosteroid injection
Description: Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in impact
Description: advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in impact
Description: advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in impact
Description: advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
Study: NCT03527550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Cognitive Control Training involves daily practice with one of two computerized interventions. The first intervention is an adaptive Go/No-Go task to provide practice in the domain of response inhibition. Participants press a key as fast as possible in response to stimuli (letters of the alphabet), but must inhibit responses to a specific letter. The second intervention is an adaptive Paced Auditory Serial Addition Task (PASAT), designed to practice working memory. Participants are presented with single numbers presented aurally, and must add each number they hear to the previous number and click the correct sum on the screen.
Study: NCT03502031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-Angiotensin (RAAS) alone
Description: maximal RAAS blockade alone for 24months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Description: maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
Study: NCT01767701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg twice daily for 3 months
Study: NCT06186661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurophysiological exercise
Description: The content of the treatment program consisted of neurophysiological exercises based on Bobath.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurophysiological exercise
Description: The content of the treatment program consisted of neurophysiological exercises based on Bobath.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive rehabilitation
Description: Cognitive rehabilitation sessions of the experimental group included 30 minutes of remedial and functional adaptive approaches and 30 minutes of implementation of Multicontextual treatment intervention.
Study: NCT01159002

Intervention type: DEVICE
Intervention: SmartPill
Description: Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
Study: NCT02502903

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIV009

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIV009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIV009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIV009

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03177499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive PPG
Description: Invasive PPG obtained by means of catheterization.
Study: NCT01844687

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.

Intervention type: DRUG
Group type: OTHER
Intervention: CBD
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Study: NCT00997893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soy Placebo
Description: oral placebo pill (0mg Soy Phytoestrogen)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MPA Placebo
Description: oral placebo pill (0mg MPA)